Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W1MU
|
|||
Former ID |
DIB004682
|
|||
Drug Name |
TBC-M4
|
|||
Synonyms |
MVA-based HIV subtype C vaccine, IAVI; Modified vaccinia Ankara-based HIV subtype C vaccine, International AIDS Vaccine Initiative
Click to Show/Hide
|
|||
Drug Type |
Vaccine
|
|||
Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
Company |
National Institute of Cholera and Enteric Diseases
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) | Target Info | . | [2] |
Human immunodeficiency virus GAG protein (HIV gag) | Target Info | . | [2] | |
Reactome | Uncoating of the HIV Virion | |||
Budding and maturation of HIV virion | ||||
Integration of provirus | ||||
Early Phase of HIV Life Cycle | ||||
Minus-strand DNA synthesis | ||||
Plus-strand DNA synthesis | ||||
2-LTR circle formation | ||||
Binding and entry of HIV virion | ||||
Membrane binding and targetting of GAG proteins | ||||
Assembly Of The HIV Virion | ||||
Integration of viral DNA into host genomic DNA | ||||
Autointegration results in viral DNA circles | ||||
APOBEC3G mediated resistance to HIV-1 infection | ||||
Vpr-mediated nuclear import of PICs | ||||
WikiPathways | Host Interactions of HIV factors | |||
HIV Life Cycle |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00902824) Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine. U.S. National Institutes of Health. | |||
REF 2 | A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.